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Aim: The aim of our study was to assess the efficacy of pulmonary rehabilitation in addition to
regular chest physiotherapy in non cystic fibrosis bronchiectasis.
Methods: Thirty patients with clinically significant bronchiectasis and limited exercise toler-
ance were randomized into either the control group receiving chest physiotherapy (8 weeks)
or into the intervention group, receiving pulmonary rehabilitation in addition to chest physio-
therapy (8 weeks).
Both groups were encouraged to maintain their exercise program and or chest physio-
therapy, following completion of the study.
Results: End of training (8 weeks)
No improvement in control group.
In the intervention group, incremental shuttle walk test (ISWT) improved by 56.7 m
(pZ 0.03), endurance walk test (EWT) by 193.3 m (pZ 0.01), Leicester Cough Questionnaire
(LCQ) improved by 2.6units (p < 0.001) and St. George’s Respiratory Questionnaire (SGRQ) by
8units (p < 0.001).
At 20 weeks (12 weeks post end of training)
No improvement in control group.
In the intervention group, ISWT improved by 80 m (p Z 0.04) and EWT by 247.5 m
(p Z 0.003). LCQ improved by 4.4 units (p < 0.001) and SGRQ by 4 units (p < 0.001).31 242 1921; fax: þ44 0131 242 1870.
oglemail.com (P. Mandal).
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1648 P. Mandal et al.Conclusion: Pulmonary rehabilitation in addition to regular chest physiotherapy, improves
exercise tolerance and health related quality of life in non cystic fibrosis bronchiectasis and
the benefit was sustained at 12 weeks post end of pulmonary rehabilitation.
Clinical trials regn no. NCT00868075.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Bronchiectasis is a chronic debilitating respiratory condi-
tion due to inflamed and permanently damaged airways.
Patients suffer daily cough, excess sputum production and
recurrent chest infections. Some patients in addition have
wheeze, dyspnoea and reduced exercise tolerance.1,2 The
cause of dyspnoea and reduced exercise capacity are
multifactorial and may include altered pulmonary
mechanics, inefficient gas exchange, decreased muscle
mass and confounding psychological morbidity.3 This leads
to a cycle of reduced exercise capacity, resulting in
progressive detraining and further reduced exercise toler-
ance and health related quality of life (HRQoL).3e6
In 1988, bronchiectasis was described as an “orphan
disease” of the airways.7 However, more than two decades
later, there is little or no evidence for the effectiveness of
most of the treatments in bronchiectasis, including inhaled
corticosteroids, bronchodilators, hyperosmolar agents,
mucolytics and even bronchopulmonary hygiene physical
therapy.8
Although, regular chest physiotherapy is considered
standard in patients with non cystic fibrosis bronchiectasis,
there is little scientific evidence to support efficacy and
effectiveness.9 In 2009, Murray et al., showed by an RCT in
non cystic fibrosis bronchiectasis, that regular chest phys-
iotherapy (in patients who did not practice regular chest
physiotherapy), led to an improvement in exercise toler-
ance and HRQoL.10
Pulmonary rehabilitation is a multidisciplinary approach
to treating patients with chronic lung disease and is advo-
cated in the guidelines of management in the American,
British and European guidelines.11e13 Newall et al. showed
that pulmonary rehabilitation is effective in improving
exercise tolerance in bronchiectasis, but simultaneous
inspiratory muscle training was required to maintain the
initial improvement.14
The aim of this pilot study was to compare the effects of
regular chest physiotherapy alone in comparison to chest
physiotherapy and pulmonary rehabilitation, in patients
with non cystic fibrosis bronchiectasis, to determine
whether pulmonary rehabilitation has an additional benefit
to regular chest physiotherapy.Methods
Study design
Thirty patients with non cystic fibrosis bronchiectasis,
confirmed by high resolution computed tomography
(HRCT), were allocated randomly (by a computer generatedrandom number sequence) to one of the two groups: (1)
control group receiving 8 weeks of twice daily chest phys-
iotherapy; and (2) intervention group receiving twice daily
chest physiotherapy plus pulmonary rehabilitation. Patients
were encouraged to maintain the exercises and or chest
physiotherapy, after the intervention ended.
In both groups assessments were performed at baseline,
at 8 weeks, and at 12 weeks after completion of study
(20 weeks) for each individual patient.
Prior to starting the study, all patients attended the
physiotherapy gym and or the laboratory to familiarize
themselves with the equipment and to minimize the effects
of test habituation. This was done on two separate days to
assess reproducibility of tests and this was achieved.
The study was approved by the Lothian Research Ethics
committee (Edinburgh, UK) and patients gave informed
written consent.
Outcome measures
The primary endpoint was improvement in the incremental
shuttle walking test (ISWT).
Power calculation for study
We based the power calculation on a previous study by
Newall et al.14 This study was powered to detect a mean
(SD) difference of 50 m (using the ISWT) between the
groups (assuming an SD of 40 m) would require 11 patients
per treatment group with 80% power and a significance
level of 0.05. This study was therefore adequately powered
for the primary endpoint.
Secondary endpoints were endurance walk test (EWT),
health status questionnaires e cough severity using LCQ15
and health related quality of life using SGRQ,16 Forced
expiratory volume in 1 s (FEV1), Forced Vital Capacity
(FVC), Maximal Inspiratory Pressure (PImax), Maximal
Expiratory Pressure (PEmax) and markers of inflammation
including, white cell count (WCC), C-reactive protein (CRP)
and erythrocyte sedimentation rate (ESR).
Patients
Patients were recruited from South East of Scotland Bron-
chiectasis Clinic in the Royal Infirmary of Edinburgh, UK, in
a prospective study.
Inclusion criteria
(1) All patients had an established radiological diagnosis of
bronchiectasis (HRCT of the chest); (2) patients had clini-
cally significant bronchiectasis expectorating mucopurulent
pulmonary rehabilitation and chest physiotherapy Vs. chest physiotherapy alone bronchiectasis 1649or purulent sputum when clinically stable; (3) clinically
stable disease with no requirement of antibiotics in the
4 weeks prior to commencing the study; (4) exercise
capacity reduced to disease process; (5) all practicing chest
clearance regularly (>4times/week) prior to study entry.
Exclusion criteria
(1) Current smokers or ex-smokers of less than 1 year; (2)
>15 pack year history; (3) cystic fibrosis; (4) active allergic
bronchopulmonary aspergillosis; (5) active tuberculosis; (6)
poorly controlled asthma.
Chest physiotherapy
Chest physiotherapy was carried out using the oscillatory
PEP device Acapella Choice (Smiths Medical ASD Inc.,
Weston, MA, USA). Patients were individually trained
by senior chest physiotherapist (J.L. Pentland). The
frequency/resistance dial (range 1e5) was set at three for
all participants. This setting was the maximum tolerated
by all participants. Patients performed three sets of the
following cycle at each session (20e30 min), twice a day.
(1). A tight seal was maintained around the mouthpiece.
(2). For 10 breaths, patients inhaled to three quarters of
the maximum inspiratory capacity then a 3-s breath hold
followed by exhalation to functional residual capacity.
(3). Then followed by two to three forceful expiratory
huffs.
Once the physiotherapist was satisfied with the patients’
technique, chest physiotherapy was done at home but was
checked at each study visit.
Technique, compliance and occurrence of any adverse
effects (specifically, any haemoptysis or increased use of
short-acting bronchodilator therapy) were assessed using
a diary card, which was reviewed at each visit. Sessions
ended with an education session (described below).
Pulmonary rehabilitation
Pulmonary rehabilitation was carried out over 8 weeks in
the physiotherapy gym in the Royal Infirmary of Edinburgh.
There were 2 supervised sessions per week and 1 unsuper-
vised session at home for 8 weeks. Patients started with
a gentle warm up, followed by 10-min sessions each on
cardiovascular equipment including the treadmill (Vision-
Fitness, USA), bike (Tunturi, Netherlands) and ski
machine (Welso Skier Plus, Welso Fitness Equipment,
USA). Patients were exercised at 85% VO2max (maximal
oxygen consumption). All exercises were demonstrated and
supervised by trained physiotherapists and modifications of
exercises were done, as per patient’s ability. Speed/resis-
tance/time/number of rest and final saturations/heart rate
and Borg score17 was recorded, at the end of each
intervention.
Sessions ended with a cool down, as in warm up, but
slower paced followed by education.
Upper and lower limb exercises
Exercises were started at 60% of patient’s 1 repetition
maximum (RM), aiming 3 sets of 10. Week 3 progressed to70% and week 5 to 80%. If patient managed 3 sets of 10 with
ease, they were progressed to 1 RM or more, according to
patient’s ability.Education session
All patients were educated about coping with breathless-
ness and the importance of regular chest physiotherapy and
given a self-management plan as well as an opportunity to
ask relevant questions. Chest clearance techniques were
taught. A dietitian discussed healthy eating options and
a pharmacist checked inhaler technique.
All patients were encouraged to continue using the
acapella, at the end of 8 weeks to aid chest clearance.
Once patients completed 8 weeks of pulmonary rehabili-
tation, they were offered free gymnasium membership for
6 months to encourage patients to continue with the
exercise program.Incremental shuttle walk test (ISWT)
Patients walked a 10 m course mapped out by two cones.
The speed gradually increased each minute. The test was
stopped if the patient was too breathless or failed to attain
the desired speed. The distance walked was recorded in
metres.18Endurance walk test (EWT)
EWT was performed as described by Revill et al.19 Patients
walked along a 10 m course demarcated by 2 cones and
turned around cones at either end of the course. The
walking pace was controlled by a series of pre-recorded
bleeps from the test CD. EWT was performed at 85% of
VO2max, measured from the ISWT.Health status
Patients were asked to complete both the Leicester
Cough Questionnaire (LCQ) and St George’s Respiratory
Questionnaire (SGRQ) at all review time points. The LCQ
has 19 items divided into 3 domains: physical (8 items),
psychological (7 items) and social (4 items). The total
severity score ranges from 3 to 21, where a lower score
indicates a greater impairment of health status due to
cough. The MCID for LCQ is 1.3 units.15 We have validated
the Leicester Cough Questionnaire for use in non cystic
fibrosis bronchiectasis.20 The SGRQ has 50 items divided
into 3 main domains, symptoms, activities and impacts.
The total score ranges from 0 to 100, where a higher
score indicates a poorer HRQoL. The MCID for SGRQ is
4 units.16Lung function
Forced Expired Volume in 1 s (FEV1), Forced Vital Capacity
(FVC) and FEV1/FVC ratio were recorded, according to
national guidelines.21
1650 P. Mandal et al.Respiratory muscle strength
Maximum Inspiratory Pressure (MIP) and Maximum Expira-
tory Pressure (MEP) were measured as per the methods
described by Black and Hyatt22 using a handheld mouth
pressure meter (MicroRPM Respiratory Pressure Meter,
Micromedical Ltd, UK). For measuring MIP, patients were
instructed to exhale to residual volume and then inhale
forcefully and maintain maximum pressure for 1 s. To
measure MEP, patients were instructed to inhale to total
lung capacity and then exhale forcefully and maintain
maximum pressure for 1 s.Blood samples
15 ml of venous blood was collected and white cell count,
ESR and CRP were measured.Statistical analysis
All data were analysed using Graphpad prism (Graphpad
software, San Diego, CA, USA). Data was normally distrib-
uted. For demographic and clinical variables, data are
presented as mean (standard error) for continuous vari-
ables and n (%) for categorical variables unless otherwise
stated. Comparison of changes between the 2 groups wasAssessed for 
Analysed  (n=15) 
♦ Excluded from analysis (give reasons)  
(n=0)
Lost to follow-up (give reasons) (n= 0) 
Discontinued intervention (give reasons)  
(n=0) 
Allocated to intervention (n=15) 
♦ Received allocated intervention (n= 15)
♦ Did not receive allocated intervention (give 
reasons) (n= 0)
Allocat
Analy
Follow
Random
Enrollment 
Figure 1 Flow chart from recruicalculated using unpaired t tests. A P-value of <0.05 was
considered statistically significant for each analysis.Results
Patients
15 patients were randomly allocated in each arm of the study,
by a computer generated program (Fig. 1). All 15 patients in
the control group completed the study. 3 patients withdrew
from the intervention group due to personal reasons (two
patients had bereavement in the family; and one patient had
a new diagnosis of terminal disease). 2 patients withdrew after
week 1 and 1 patient withdrew at week 3. Baseline charac-
teristics of the study population is summarized in Table 1.
1. Exercise capacity (Fig. 2 and Table 2)
End of training
No improvement in acapella group.
In the intervention group, there was an improvement in
the ISWT by 56.7 m (p Z 0.03) and the EWT by 193.3 m
(p Z 0.01).
At 20 weeks
No improvement in acapella group. The mean distance
walked at the end of the study was similar to baselineeligibility (n=38) 
Excluded  (n=8) 
♦ Not meeting inclusion criteria (n=2) 
♦ Declined to participate (n=5) 
♦ Other reasons (n= 1) 
Lost to follow-up (give reasons) (n=0) 
Discontinued intervention (give reasons) (n=3; 
dropped out due to personal reasons) 
Allocated to intervention (n=15) 
♦ Received allocated intervention (n=15)
♦ Did not receive allocated intervention 
(give reasons) (n= 0)
Analysed  (n= 12) 
♦ Excluded from analysis (give reasons)  
(n=0)
ion
sis
-Up
ized (n=30) 
tment to completion of study.
Table 1 Baseline characteristics of study population;
there was no statistically significant difference between the
two groups at baseline.
Group
receiving
acapella
(n Z 15)
Group receiving
acapella þ pulmonary
rehabilitation (n Z 12;
3 withdrew)
Age 64.6 (3.4) 64.8 (3.7)
Gender (% male) 40% 66.7%
Smoking status (Never) 33.3% 58.3%
Inhaled corticosteroids 80% 91.6%
Radiological severity
(3 lobes)
40% 41.7%
Chronically colonized 80% 91.6%
Chronically colonized
with Pseudomonas
aeruginosa
26.7% 33.3%
FEV1 (L) 1.9 (0.3) 1.9 (0.3)
FEV1 (% predicted) 72% 76%
PImax (cm H2O) 56.1 (6.1) 63.4 (9.1)
PImax (% predicted) 85% 89%
PEmax (cm H2O) 85 (8.2) 73 (10.9)
PEmax (% predicted) 68% 62%
ISWT (m) 343.3 (44.4) 287.5 (50.6)
EWT (m) 1021.4
(144.4)
1102.5 (116.2)
pulmonary rehabilitation and chest physiotherapy Vs. chest physiotherapy alone bronchiectasis 1651(343.3 m at the start and completion of study). In the
intervention group, there was an improvement in the ISWT
by 80 m (p Z 0.04) and the EWT by 247.5 m (p Z 0.003).
2. Health related quality of life
There was no significant difference in the health status
at baseline between the two groups (see Table 3).
End of training
No improvement in acapella group.
In the intervention group, there was a 2.6 unit
improvement in the LCQ (the MCID for LCQ is 1.3 units) anda
Figure 2 Figure (a and b) showing the mean (þ/SE) of the dista
represent differences between the 2 groups, at time points indicaan 8 unit improvement in the SGRQ total score (the MCID for
SGRQ is 4 units).
At 20 weeks
No improvement in acapella group.
In the intervention group, there was a 4.4 unit
improvement in the LCQ (the MCID for LCQ is 1.3 units) and
a 4 unit improvement in the SGRQ total score (the MCID for
SGRQ is 4 units) (Table 3).
3. Spirometry and respiratory muscle function
There was no improvement in spirometry or respiratory
muscle function in either groups (see Table 4).
4. Inflammatory markers
There was no significant change in the inflammatory
makers at the different time points, in either groups and is
shown in Table 5.
Discussion
This pilot study in non cystic fibrosis bronchiectasis, found
that pulmonary rehabilitation in addition to regular chest
physiotherapy led to significant improvement in exercise
capacity and health related quality of life as compared to
patients practicing regular chest physiotherapy alone, and
this was maintained at 12 weeks after the intervention
ended. However, this did not result in any significant
improvement in the secondary outcome measures-FEV1,
FVC, PImax, PEmax or inflammatory markers including
WCC, CRP and ESR. Based on a previous study by Newall
et al.,14 our study was adequately powered to detect
a change in exercise capacity.
At our centre, pulmonary rehabilitation included
training with 3 different cardiovascular equipments. In
addition patients were educated about chest clearance
techniques, given self-management plans and inhaler
techniques were checked.
Our study showed that pulmonary rehabilitation in
addition to regular chest physiotherapy led to improvementB
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ted. *p Z 0.03; **p Z 0.04; #p Z 0.01, ##p Z 0.003.
Table 2 p values represent difference between groups at time points indicated.
Group receiving acapella (n Z 15) Group receiving acapella þ pulmonary rehabilitation
(n Z 12)
Baseline 8 weeks 20 weeks Baseline 8 weeks 20 weeks
ISWT (m) 343.3 (44.4) 338.7 (42.2) 343.3 (39.8) 287.5 (50.6) 344.2 (115.5)* 367.5 (61.5)**
EWT (m) 1021.4(144.4) 985 (168.6) 964.3 (165.7) 1102.5 (116.2) 1295.8 (65.8) # 1350 (72.6) ##
*p Z 0.03; **p Z 0.04; #p Z 0.01; ##p Z 0.003.
Table 3 p values represent difference between groups at time points indicated.
Group receiving acapella (n Z 15) Group receiving acapella þ pulmonary
rehabilitation (n Z 12)
Baseline 8weeks 20weeks Baseline 8weeks 20 weeks
SGRQ 40.6 (3.9) 39.2 (4.5) 45.2 (4.5) 38.6 (6.4) 30.6 (6.6)* 34.6 (7.7)*
LCQ 14.4 (1.5) 14.6 (1.4) 13.62 (1.4) 12.3 (2.3) 14.9 (2.3)* 16.7 (1.8)*
*p < 0.001.
1652 P. Mandal et al.in both the incremental shuttle walk test and the endur-
ance walk test, in comparison to the group practicing chest
physiotherapy alone, on completion of training. This
improvement was maintained at 20 weeks (12 weeks post
completion of study). Following end of training, patients in
both groups were encouraged to maintain their exercise
program and or chest physiotherapy.
Pulmonary rehabilitation is now recommended as the
standard of care for patients with chronic obstructive lung
disease.23 Exercise and self-management training, as a part
of pulmonary rehabilitation program, is a well established
and effective intervention in chronic obstructive pulmonary
disease. This leads to reduced exacerbations and subse-
quently health care utilization, improved exercise capacity
and heath related quality of life.24e28 There are marked
similarities in the disease manifestations of COPD and
bronchiectasis, with both conditions having a primary
pulmonary involvement and having secondary peripheral
muscle, nutritional and health related quality of life
impairment.29 In respiratory medicine there is often
extrapolation of treatment modalities for which evidence
has been gained in one clinical condition, to another
condition. However this needs to be done with caution and
needs to be supported by good evidence. In a systematic
review in 2002, Bradley et al. concluded that there wasTable 4 No statistically significant change in secondary outcom
or intervention group, at any of the time points shown.
Group receiving acapella (n Z 15)
Baseline 8 weeks 20 we
FEV1(L) 1.9 (0.3) 1.9 (0.3) 1.9 (
FVC(L) 2.7 (0.3) 2.7 (0.3) 2.8 (
PImax (cm H2O) 56.1 (6.1) 62 (4.8) 51.1 (
PEmax (cm H2O) 85 (8.2) 90.3 (9.1) 77.6 (a need for well designed, adequately powered, randomized
controlled clinical trials to assess the benefit of adhering to
different forms of physiotherapy in bronchiectasis.3 Three
significant studies addressing chest physiotherapy and
pulmonary rehabilitation, in bronchiectasis have been done
to date. In 2005, Newall et al. showed that in bronchiec-
tasis, pulmonary rehabilitation in addition to inspiratory
muscle training (IMT) improved exercise tolerance and
health status and this was maintained at 3 months after
completion of study.14 Addition of IMT was required to
maintain the longevity of the training effects.14 In a large
retrospective study in 2011, it was shown that pulmonary
rehabilitation in bronchiectasis led to significant improve-
ment in patients’ exercise tolerance and health status. This
was comparable to the improvements in the COPD group
receiving pulmonary rehabilitation.30 However, prospective
studies are needed to substantiate these findings. In 2009,
in a cross over RCT in non cystic bronchiectasis in patients
not practicing regular chest physiotherapy, we showed that
regular chest physiotherapy in comparison to no chest
physiotherapy, led to an improvement in exercise tolerance
and HRQoL.10 There was no improvement in the control
group in the current study. This may reflect the fact that all
patients, as part of the inclusion criteria, were already
practicing regular chest physiotherapy prior to starting thee measures (FEV1, FVC, PImax or PEmax) in either the control
Group receiving acapella þ pulmonary
rehabilitation (n Z 12)
eks Baseline 8 weeks 20 weeks
0.3) 1.9 (0.3) 2.1 (0.4) 2.1 (0.4)
0.3) 2.9 (0.3) 3.1 (0.4) 2.9 (0.4)
4.4) 63.4 (9.1) 70 (12.9) 75.1 (11.9)
10.7) 73 (10.9) 87.7 (12.8) 93.8 (15.2)
Table 5 No statistically significant change in secondary outcome measures (WCC, CRP or ESR) in either the control or
intervention group, at any of the time points shown.
Group receiving acapella (n Z 15) Group receiving acapella þ pulmonary
rehabilitation (n Z 12)
Baseline 8weeks 20weeks Baseline 8weeks 20 weeks
WCC*109/L 6.5 (0.6) 6.9 (0.8) 6.9 (0.8) 8.3 (0.9) 8.2 (0.8) 8.1 (0.8)
CRP mg/L 4.9 (1.2) 5.5 (1.6) 5.2 (1.3) 7.9 (2.9) 9.5 (2.6) 5.2 (1.6)
ESR mm/hr 14.9 (2.3) 12.1 (2.2) 13.7 (3.3) 14.2 (2.7) 18.2 (4.3) 15.3 (2.9)
pulmonary rehabilitation and chest physiotherapy Vs. chest physiotherapy alone bronchiectasis 1653study. Larger studies are needed with physiotherapy alone
to evaluate other outcome measures such as exacerbations.
Limitations
We acknowledge that our study had limitations. Firstly, the
size of the study was small. Secondly no information was
collected on the intensity of ongoing training activities in
the intervention group between weeks 8 and 20. Although
all patients in this group were offered free gymnasium
membership for 6 months, it would have been helpful to
know the take up and frequency of exercise intervention.
Finally exacerbations were treated by their primary care
physician and this data was not collected for this pilot
study.
Conclusion
In summary, our pilot study showed that pulmonary reha-
bilitation improved exercise capacity and health related
quality of life and this was sustained at 12 weeks post
completion of intervention. Large multicentre studies are
needed to address key secondary endpoints such as the
effect on exacerbations.
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